Type 2 diabetes: Complications and comorbidities

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

Severe hypoglycemia in people with type 2 diabetes is associated with later mortality from a wide range of causes, including those for which there is no obvious underlying mechanism, say researchers.

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

A large observational study reveals a strong link between reduced kidney function and increased incidence of hypoglycemia in adults with diabetes in routine clinical practice.

Optimal glycemic control during the first years after a latent autoimmune diabetes of adulthood diagnosis could prevent people’s microvascular complication risk from equaling that seen in those with type 2 diabetes, shows an analysis of the UKPDS.

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

People with type 2 diabetes and reduced kidney function in the absence of albuminuria have an increased risk for mortality and major adverse cardiovascular events, despite a low risk for end-stage renal disease, research shows.

Fasting C-peptide levels can “provide valuable information” to guide the approach to titrating basal insulin in new users with type 2 diabetes, say researchers.

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

People who undergo bariatric surgery have a lower long-term risk for mortality, but a higher risk for adverse events such as gastrointestinal and nutritional disorders, compared with those who do not undergo surgery, researchers report.

Read the linked commentary from John Wilding

Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.